drugset / Trial / NCT07533136
Tafenoquine Combinations for Improved Radical Cure Efficacy of Plasmodium Vivax
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is to conduct a clinical trial of tafenoquine combinations to compare the rates of therapeutic efficacy of dihydroartemisinin-piperaquine or artemether-lumefantrine with tafenoquine to chloroquine plus tafenoquine in preventing recurrence of Plasmodium vivax over a 6-month period in adult subjects with uncomplicated P. vivax infection living in Thailand.
Timeline
- Start
- 2026-05-01
- Primary completion
- 2028-10-31
- Completion
- 2029-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | ARTENIMOL | Small molecule | 40 mg | — |
| Comparator | Artemether | Small molecule | 20 mg | — |
| Comparator | Chloroquine | Small molecule | 150 mg | — |
| Comparator | Tafenoquine | Small molecule | 300 mg | — |
| Comparator | lumefantrine | Small molecule | 120 mg | — |
| Comparator | piperaquine | Small molecule | 320 mg | — |